KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Revenue: 2009-2025

Historic Revenue for Pacira BioSciences (PCRX) over the last 16 years, with Sep 2025 value amounting to $179.5 million.

  • Pacira BioSciences' Revenue rose 6.49% to $179.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $716.8 million, marking a year-over-year increase of 3.14%. This contributed to the annual value of $701.0 million for FY2024, which is 3.85% up from last year.
  • As of Q3 2025, Pacira BioSciences' Revenue stood at $179.5 million, which was down 0.87% from $181.1 million recorded in Q2 2025.
  • Pacira BioSciences' 5-year Revenue high stood at $187.3 million for Q4 2024, and its period low was $119.0 million during Q1 2021.
  • Over the past 3 years, Pacira BioSciences' median Revenue value was $169.5 million (recorded in 2023), while the average stood at $173.2 million.
  • Per our database at Business Quant, Pacira BioSciences' Revenue spiked by 79.58% in 2021 and then decreased by 2.11% in 2023.
  • Pacira BioSciences' Revenue (Quarterly) stood at $159.2 million in 2021, then rose by 8.02% to $172.0 million in 2022, then increased by 5.40% to $181.2 million in 2023, then rose by 3.32% to $187.3 million in 2024, then climbed by 6.49% to $179.5 million in 2025.
  • Its Revenue stands at $179.5 million for Q3 2025, versus $181.1 million for Q2 2025 and $168.9 million for Q1 2025.